Related Experiment Video
Updated: Sep 9, 2025

Mutagenesis and Analysis of Genetic Mutations in the GC-rich KISS1 Receptor Sequence Identified in Humans with Reproductive Disorders
Published on: September 4, 2011
Deciphering protein-DNA interactions of KISS1 with transcription factors through molecular docking, molecular
Hetvi Shah1, Pranav Pillai2, Lipi Buch2
1TREE Lab, Department of Biomedical and Life Sciences, School of Science, Navrachana University, Vadodara, India.
Abstract:
Metastasis is a key hallmark of cancer aggressiveness, particularly in triple-negative breast cancer (TNBC), which lacks effective targeted therapies. Kisspeptin-1 (KISS1), a known metastasis suppressor is emerging as a potential therapeutic modulator. This study investigates the structural and regulatory interactions between KISS1 and key transcription factors (TFs) involved in metastasis: SP1, CDX2, FLI1, GATA2, NMYC, and HDAC2. TFs were identified via TFLink, modelled using SWISS-MODEL, and docked with KISS1-DNA using HADDOCK. CDX2 showed the strongest binding (HADDOCK score: -144.2; buried surface area: 2526.5 Å2), followed by HDAC2, GATA2, NMYC, SP1, and FLI1. Molecular dynamics simulations (150 ns) revealed stable complexes for SP1, NMYC, and CDX2 with low RMSD (2.1-2.7 Å), compact Rg (∼21.0 Å), and stable hydrogen bonding (5-9 bonds). In contrast, FLI1 and GATA2 showed greater flexibility and unstable interactions. Experimental validation in MDA-MB-231 cells treated with Kisspeptin-10 (IC50: 100.21 nM) showed upregulation of SP1, NMYC, CDX2, and GATA2, and downregulation of FLI1 and HDAC2. These findings suggest KISS1 selectively modulates transcriptional activity toward anti-metastatic signaling. Overall, KISS1 demonstrates strong potential as a transcriptional regulator and therapeutic agent against TNBC metastasis.
Insights
Kisspeptin-1 (KISS1) modulates key transcription factors to suppress metastasis in triple-negative breast cancer (TNBC). This study reveals KISS1
Area of Science:
- Cancer Biology
- Molecular Oncology
- Structural Biology
Background:
- Metastasis is a critical challenge in triple-negative breast cancer (TNBC), lacking targeted therapies.
- Kisspeptin-1 (KISS1) is a known metastasis suppressor with therapeutic potential.
- Understanding KISS1's interaction with transcription factors (TFs) is crucial for TNBC treatment.
Purpose of the Study:
- Investigate structural and regulatory interactions between KISS1 and metastasis-associated TFs.
- Determine the binding affinity and stability of KISS1-TF complexes.
- Validate the effect of KISS1 on TF expression in TNBC cells.
Main Methods:
- TF identification using TFLink and molecular modeling with SWISS-MODEL.
- Protein-DNA docking simulations using HADDOCK to assess binding.
- Molecular dynamics simulations (150 ns) to analyze complex stability.
- Experimental validation in MDA-MB-231 cells treated with Kisspeptin-10.
Main Results:
- CDX2 exhibited the strongest binding to KISS1-DNA, followed by HDAC2, GATA2, NMYC, SP1, and FLI1.
- Molecular dynamics simulations confirmed stable complexes for SP1, NMYC, and CDX2.
- Kisspeptin-10 treatment upregulated SP1, NMYC, CDX2, GATA2, and downregulated FLI1 and HDAC2 in TNBC cells.
- KISS1 selectively modulates TF activity towards anti-metastatic signaling.
Conclusions:
- KISS1 acts as a selective transcriptional regulator in TNBC metastasis.
- The findings highlight KISS1's potential as a therapeutic agent against TNBC metastasis.
- Further research into KISS1-mediated transcriptional regulation could yield novel anti-cancer strategies.
More Related Videos
Related Concept Videos
Cooperative Binding of Transcription Regulators
RNA Polymerase II Accessory Proteins
Co-activators and Co-repressors

